Search Patents
  • Recombinant poly(A) polymerase
    Patent number: 5525497
    Abstract: Purified nucleic acid encoding a yeast, human, or bovine poly(A) polymerase, where the bovine nucleic acid consists essentially of that nucleic acid sequence shown as nucleotide SEQ. ID. NO.: 1; the resulting recombinant poly(A) polymerase expressed from these nucleic acids, corresponding methods of their production, and methods of use of the poly(A) polymerase.
    Type: Grant
    Filed: November 27, 1991
    Date of Patent: June 11, 1996
    Inventors: Walter Keller, Joachim Lingner, Georges Martin, Elmar Wahle
  • Alkaline bacillus lipases, coding DNA sequences therefor and bacilli, which produce these lipases
    Patent number: 5427936
    Abstract: The invention relates to alkaline bacillus lipases, DNA sequences, which code for these lipases, a method for isolating and producing these lipases, as well as to bacillus strains, which have the capability to form these lipases. The alkaline lipases are suitable for use in compositions for cleaning, washing and bleaching purposes.
    Type: Grant
    Filed: October 13, 1992
    Date of Patent: June 27, 1995
    Assignee: Kali-Chemie Aktiengesellschaft
    Inventors: Bernhard Moeller, Roman Vetter, Detlef Wilke, Birgit Foullois
  • Compositions and treatment for herpes simplex
    Patent number: 5149529
    Abstract: A method for preventing or ameliorating HSV infection in a bird or mammal comprises administering a composition comprising an effective amount of an HSV surface glycoprotein and an effective amount of an MDP equivalent, encapsulated in liposomes. The resulting composition is useful for reducing the severity and recurrence of HSV outbreaks.
    Type: Grant
    Filed: October 11, 1991
    Date of Patent: September 22, 1992
    Assignees: Board of Trustees of Leland Chiron Corporation, Stanford Junior University
    Inventors: Rodney Ho, Thomas Merigan, Rae L. Burke, Dino Dina
  • Removal of protein A from antibody preparations
    Patent number: 4983722
    Abstract: Protein A is selectively isolated from an antibody--Protein A mixture by exposing the mixture to an anion exchange material under conditions sufficient to adsorb both components and then sequentially eluting the antibodies and protein A under conditions of increasing ionic strength. Resulting antibody preparations have less than about 15 ng of Protein A per mg of antibody.
    Type: Grant
    Filed: June 8, 1988
    Date of Patent: January 8, 1991
    Assignee: Miles Inc.
    Inventors: James W. Bloom, Melvin F. Wong, Gautam Mitra
  • Process for preparing lipases
    Patent number: 5681715
    Abstract: A process for producing an active lipase enzyme in vitro, comprising mixing an inactive or partly active lipase enzyme with a chaperone molecule and subjecting the mixture to denaturation followed by renaturation to produce the active lipase enzyme.
    Type: Grant
    Filed: March 3, 1995
    Date of Patent: October 28, 1997
    Assignee: Novo Nordisk A/S
    Inventors: Steen Troels J.o slashed.rgensen, Boerge Krag Diderichsen, Catherine M. Buckley, Audrey Hobson, David J. McConnell
  • Urinary follicle stimulating hormone
    Patent number: 5128453
    Abstract: Purification of human FSH from post-menopausal urine gonadotropin using immunoaffinity chromatography with elution at high pH and reverse-phase HPLC steps yields a biologically active hormone which is free from detectable traces of luteinizing hormone and other urinary proteins.
    Type: Grant
    Filed: February 7, 1989
    Date of Patent: July 7, 1992
    Assignee: Istituto DiRicerca Cesare Serono SpA
    Inventors: Guiseppe Arpaia, Serenella Serani, Antonino Sirna, Stefano Villa
  • Suppression of megakaryocytopoiesis employing platelet factor 4 antimaturation factor
    Patent number: 5185323
    Abstract: Antimaturation factor (platelet factor 4 or active peptide segments thereof) is employed in the clinical treatment of coagulation disorders as an anticoagulant operating via an autoregulator mechanism for selectively suppressing megakaryocytopoiesis. Exposure of immature megakaryocytes to antimaturation factor reversibly inhibits cell maturation and, accordingly, functions characteristic of the mature cell, including platelet production and expression of genes coding for platelet coagulation factors, are reversibly suppressed.
    Type: Grant
    Filed: March 31, 1988
    Date of Patent: February 9, 1993
    Assignee: Temple University
    Inventor: Alan M. Gewirtz
  • Production of proteins in active forms
    Patent number: 5008377
    Abstract: A method for the preparation of a protein in a physiologically active or native form, which method includesproviding a source of protein in a solubilized form,and a cationic exchange medium;contacting the source of protein and cationic exchange medium; andrecovering the protein in a physiologically active form.
    Type: Grant
    Filed: April 21, 1988
    Date of Patent: April 16, 1991
    Assignee: Bunge (Australia) Pty. Ltd.
    Inventors: Joseph J. Patroni, Malcolm R. Brandon
  • Monoclonal antibody, polypeptides and production thereof
    Patent number: 5439886
    Abstract: The present invention relates to a monclonal antibody capable of suppressing the motility of cancer cells, a polypeptide recognizable by said anti-cancer antibody and its fragment peptides which is capable of suppressing the motility of cancer cells.The present invention also relates to a production and a use for preventing the matastasis of cancer thereof.
    Type: Grant
    Filed: June 6, 1994
    Date of Patent: August 8, 1995
    Assignee: Takeda Chemical Industries, Ltd.
    Inventors: Shuichi Ikeyama, Masaru Koyama, Masayuki Miyake, Masaharu Senoo
  • Process for heat treating fibrinogen
    Patent number: 5116950
    Abstract: An aqueous solution containing fibrinogen is heated in the presence of at least a sugar, an amino acid and a magnesium salt to thereby inactivate virus(es) possibly contaminating said fibrinogen. According to this process, the inactivation of the contaminating viruses can be achieved while maintaining the activity of the fibrinogen. Thus a highly safe fibrinogen preparation of excellent qualities can be prepared on an industrial scale.
    Type: Grant
    Filed: April 21, 1988
    Date of Patent: May 26, 1992
    Assignee: Green Cross Corporation
    Inventors: Kenmi Miyano, Kenji Tanaka, Hideo Nishimaki, Yoshiro Iga
  • Production of proteins in active forms
    Patent number: 4966963
    Abstract: A method for the preparation of proteins in biologically active form including providing a source of protein solubilized from inclusion bodies with a cationic surfactant; providing a weak denaturing agent; and contacting the solubilized protein with the weak denaturant in water in an amount sufficient to allow the protein to remain in a biologically active form.
    Type: Grant
    Filed: February 11, 1988
    Date of Patent: October 30, 1990
    Assignee: Bunge (Australia) Pty. Ltd.
    Inventor: Joseph J. Patroni
  • M-RNA purification
    Patent number: 5459253
    Abstract: A method kit for purification of m-RNA from a cell are disclosed. Guanidine containing moieties, at high molarity, are use to quickly lyse the cell. They also act to inhibit RNase activity. Without the need for isolation of total RNA, the lysate can then be directly purified from the lysate using oligo dT (or U) by reducing the guanidine concentration via a dilution step.
    Type: Grant
    Filed: May 2, 1994
    Date of Patent: October 17, 1995
    Assignee: Pharmacia P-L Biochemicals Inc.
    Inventors: Christopher D. Wolin, Phillip P. Franciskovich
  • Process for producing heme proteins
    Patent number: 5744323
    Abstract: The present invention relates to methods for producing heterologous heme proteins extracellularly comprising transforming a filamentous fungus with a vector comprising a DNA sequence encoding the heterologous heme protein and a DNA sequence encoding a preregion permitting secretion of the expressed heme protein, and culturing the transformed filamentous fungus in a suitable culture medium to produce the heme protein.
    Type: Grant
    Filed: September 30, 1994
    Date of Patent: April 28, 1998
    Assignee: Novo Nordisk A/5
    Inventors: Henrik Dalb.o slashed.ge, Ejner Bech Jensen, Karen Gjesing Welinder
  • Methods for the isolation of heparin-binding brain mitogens
    Patent number: 5270449
    Abstract: A group of growth factors, designated heparin-binding brain mitogens (HBBMs), is disclosed. The HBBMs are isolated from brain tissue by a sequence of purification steps. The growth factors may be useful in the promotion of angiogenesis, such as in the promotion of wound healing, bone healing and in the treatment of burns, as well as in promoting the formation, maintenance and repair of tissue, in particular, neural tissue.
    Type: Grant
    Filed: September 14, 1992
    Date of Patent: December 14, 1993
    Assignee: American Cyanamid Company
    Inventors: Peter Bohlen, Peter Gautschi-Sova
  • Method for the purification of vitamin K-dependent proteins
    Patent number: 4981952
    Abstract: The recovery of vitamin K-dependent proteins produced by transformed microorganisms can be effected from the cell culture medium utilizing the changes in the protein which occur in the presence of divalent cations. The present process uses divalent cations to alter the binding affinity of the proteins and thereby selectively elute the proteins away from contaminants in the culture medium using standard chromatography.
    Type: Grant
    Filed: August 16, 1989
    Date of Patent: January 1, 1991
    Assignee: Eli Lilly and Company
    Inventor: S. Betty Yan
  • Production of proteins in active forms
    Patent number: 4992531
    Abstract: A method for the recovery of proteins in a solubilized form from host cells including providing a source of host cells incorporating a synthesized or expressed protein; providing a source of at least one cationic surfactant; and treating the host cells with at least one cationic surfactant, in an amount sufficient to effect solubilization of the proteins.
    Type: Grant
    Filed: June 13, 1988
    Date of Patent: February 12, 1991
    Assignee: Bunge (Australia) Pty. Ltd.
    Inventors: Joseph J. Patroni, Malcolm R. Brandon
  • Biocidal proteins
    Patent number: 5482928
    Abstract: Biocidal proteins isolated from Mirabilis have been characterized. The proteins show a wide range of antifungal activity and are active against gram-positive bacteria. DNA encoding the proteins has been isolated and incorporated into vectors. Plants transformed with this DNA have been produced. The proteins find commercial application as antifungal or antibacterial agents; transformed plants will show increased disease-resistance.
    Type: Grant
    Filed: December 20, 1993
    Date of Patent: January 9, 1996
    Assignee: Imperial Chemical Industries PLC
    Inventors: Miguel De Bolle, Willem F. Broekaert, Bruno P. A. Cammue, Sarah B. Rees, Jozef Vanderleyden
  • A43 kDa antigenic protein of Bordetella recognized by polyclonal antibodies to adenylate cyclase but devoid of calmodulin-activatable adenylate cyclase activity
    Patent number: 5095094
    Abstract: The proteins of the invention are specifically recognized by polyclonal anti-AC antibodies raised against purified AC preparations, devoid of adenylate cyclase CaM-activable activity and devoid of affinity for CaM.
    Type: Grant
    Filed: February 20, 1990
    Date of Patent: March 10, 1992
    Assignees: Institut Pasteur, Institut National de la Sante et de la Recherche Medicale
    Inventors: Colette Brezin, Hoang-Oanh Nghiem, Jean Luc Boucaud, Jean M. Alonso
  • Insecticidally effective spider toxin
    Patent number: 5457178
    Abstract: This invention provides a family of insecticidally effective proteins and particular members of that family which may be isolated from the venom of the spider Filistata hibernalis, DNA encoding such proteins, insecticidal compositions of these proteins or the DNA encoding them, and methods for controlling invertebrate pests. Recombinant expression vectors and host cells and methods for producing insecticidally effective peptides are also provided.
    Type: Grant
    Filed: July 7, 1993
    Date of Patent: October 10, 1995
    Assignees: FMC Corporation, NPS Pharmaceuticals, Inc.
    Inventors: John R. H. Jackson, Karen J. Krapcho, Janice H. Johnson, Robert M. Kral, Jr.
  • Glycoprotein and gene coding therefor
    Patent number: 5521296
    Abstract: The present invention provides a glycoprotein derived from human cell membrane, which has a molecular weight of 20 to 25 Kd as estimated by SDS polyacrylamide gel electrophoresis, and contains N-glycoside type carbohydrate chain and phosphatidylinositol, and possesses an inhibitory activity to complement-mediated cell membrane damage. The present invention further provides a gene coding for the glycoprotein, and a method for the production of the glycoprotein and the gene therefor.
    Type: Grant
    Filed: August 1, 1991
    Date of Patent: May 28, 1996
    Assignees: Hidechika Okada, Mitsubishi Kasei Corp.
    Inventors: Hidechika Okada, Noriko Okada, Yoichi Nagami, Kazuhiro Takahashi, Hisao Takizawa, Jun Kondo
Narrow Results

Filter by US Classification